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ONCHOCERCIASIS AND TRACHOMA
Onchocerciasis and trachoma control: 
what has changed in the past two decades?
Trachoma and onchocerciasis are 
the two major infectious causes of 
blindness worldwide. Twenty years 
ago, the possibility of achieving 
worldwide and long-term control of 
these ancient scourges seemed 
remote and existing control 
programmes were deemed to have 
limited prospects. The picture is 
very different today: large-scale 
interventions to control both 
diseases are not only expanding, 
but control and even elimination are 
now being discussed as real 
achievable goals in a growing 
number of countries. As we will show 
in this mainly programmatic review, 
this is a remarkable achievement 
over only two decades! 
From slow and 
uncertain beginnings 
to large-scale efforts
Onchocerciasis
Up until the late 1980s (see Table 1), 
the only established disease control 
activity was the Onchocerciasis Control 
Programme (OCP), a World Health 
Organization (WHO) programme jointly 
sponsored by the World Bank, the United 
Nations, and a coalition of over 20 donor 
countries and agencies. Set up in 1974 in 
seven, then 11, countries in West Africa, 
OCP was the first programme to demon-
strate that control of onchocerciasis as a 
public health problem was indeed possible. 
However, many thought this concerned only 
11 countries. Moreover, neither the strategy 
(vector control), nor the tools developed by, 
and for, OCP operations (weekly aerial appli-
cations of larvicide, ongoing monitoring of 
community microfilarial loads and flies’ 
infectivity, etc.), nor the financial support 
available at the time, would lend 
themselves to further extension of 
control activities to the other 
endemic countries (19 in Africa and 
six in Central and Latin America).1
All this changed in 1987 with 
a first and historic donation of 
ivermectin (Mectizan®) by Merck & 
Co.2 For the first time, a safe and 
effective microfilaricide was not only 
available, but, as subsequent 
studies quickly established, could 
lend itself to mass treatments in 
high-risk, endemic communities. 
The wide and generous availability 
of Mectizan® also accelerated 
operational research activities and 
the development of new tools – for 
example Rapid Epidemiological 
Mapping of Onchocerciasis (REMO) 
was developed to precisely map 
all priority areas in each endemic 
country3 and it emerged that 
Community-Directed Treatment 
with Ivermectin (CDTI) was the most 
appropriate and cost-effective 
method for community-wide 
delivery of the new drug. CDTI was 
advocated when the African 
Programme for Onchocerciasis 
Control (APOC) was launched in 1995, 
and it remains the current strategy 
of all programmes today. In addition, 
CDTI is now being used to distribute 
other public health interventions such as 
vitamin A and bednets to prevent malaria.
Looking back, this historic and still unsur-
passed donation of Mectizan®, “to as many 
as need it, for as long as needed,” is the 
one essential ingredient that has uniquely 
impacted nearly every major development in 
the worldwide fight against onchocerciasis 
since then. It has also inspired other major 
drug donation initiatives, such as that of 
albendazole by GlaxoSmithKline in 1998 for 
lymphatic filariasis, and that of azithromycin 
by Pfizer Inc. for trachoma the same year. 
Trachoma
Modern efforts to control trachoma date 
back to the early 1950s, with the estab-
lishment, through WHO’s support, of 
national programmes in endemic countries 
in the Western Pacific, Asia, and the Middle 
East (see Table 2). These activities also 
included the assessment of the magnitude 
of blinding trachoma in these regions and 
the institution, where feasible, of operational 
research on treatment options. However, 
these efforts were rarely sustained. This was 
due partly to the lack of a simple tool to 
assess and grade trachoma and to the 
nearly insurmountable challenge of 
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Date Key event
1974 OCP is established in West Africa, using vector control as the sole strategy •	
1987 Mectizan •	 ® Donation Programme is launched
1989– 
1990
Large community-scale trials show the benefit of Mectizan •	 ®
First NGDO-supported Mectizan •	 ® distribution projects, using mobile strategies 
1992 The NGDO Group for Mectizan •	 ® distribution is established within the WHO 
Prevention of Blindness Programme
OEPA is launched  •	
1994 REMO is developed to define priority areas for disease control  •	
1995 CDTI is recommended as a safe and cost-effective strategy for  •	
onchocerciasis control
APOC is launched •	
1999 VISION 2020 is launched •	
2002 OCP winds down its activities •	
Table 1. A chronological outline of the development of onchocerciasis control 
programmes since 1974
Continues overleaf ➤
The donation of Mectizan® by Merck & Co from 1987 
has had a unique impact on the worldwide fight 
against onchocerciasis
S
u
z
a
n
n
e
 
P
o
r
t
e
r
/
S
i
g
h
t
s
a
v
e
r
s
.
 
C
A
M
E
R
O
O
N
Daniel Etya’ale
Coordinator of VISION 2020 
in Africa, Programme for the 
Prevention of Blindness, 
World Health Organization, 
20 Avenue Appia, CH-1211 
Geneva 27, Switzerland.44
fostering community-wide compliance for a 
six-week treatment regimen of twice-daily 
application of a tetracycline ointment, in the 
absence of parallel measures to transform 
at the same time the environment in which 
trachoma thrives. As a result, trachoma 
attracted only marginal public interest until 
the mid-1990s.4
The introduction of the simplified grading 
scheme for trachoma in 1987 and of the 
SAFE strategy (Surgery, Antibiotics, Facial 
cleanliness and Environmental changes) in 
1996 by WHO5 represented crucial opera-
tional milestones in trachoma control. This 
led to three important developments, which 
provided the impetus needed to put this 
ancient disease back on the world map in 
the mid-1990s: (i) the establishment of the 
WHO GET 2020 alliance (Global Elimination 
of Blinding Trachoma by the Year 2020), 
providing the mandate and framework for 
trachoma control worldwide; (ii) the donation 
of azithromycin by Pfizer Inc. in 1997; and 
(iii) the subsequent establishment in 1998 
of the International Trachoma Initiative (ITI), 
to manage this donation. This served as a 
catalyst to expand and accelerate ongoing 
control activities, a process further facili-
tated by the ease with which azithromycin 
can be administered even on a large scale 
(a single oral dose in most cases, as opposed 
to the six-week tetracycline regimen). 
Some major achievements 
to date
Onchocerciasis
OCP wound down its activities in 2002, having 
achieved the prevention of 600,000 cases 
of blindness and protected a further 
40 million people from ocular morbidity 
throughout large areas in West Africa. 
However, it was also agreed that in order 
to prevent recurrence of the disease and 
consolidate these important gains, 
distribution of Mectizan® must be 
continued, with high coverage, and robust 
surveillance systems established and 
maintained. 
Elsewhere, control activities now cover 
nearly all known meso- and hyper-endemic 
areas around the world. APOC thus aims to 
protect some 92 million at-risk individuals 
from the deleterious effects of river 
blindness; currently more than half of them 
are under annual Mectizan® treatment. 
Similarly, the Onchocerciasis Elimination 
Programme for the Americas (OEPA) has 
established, in all six endemic countries, 
effective national programmes in all 13 foci 
with a treatment coverage of at least 85% 
twice a year. Even more significantly in 2007, 
all eye lesions attributable to onchocerciasis 
had been eliminated in nine of these 13 foci.
Trachoma
An increasing number of endemic 
countries are now receiving support for 
baseline surveys, national plan devel-
opment, the implementation of the 
SAFE strategy, and the development and 
use of appropriate indicators for monitoring 
and evaluation purposes. Others, like 
Morocco, the first country to have 
completed its campaign for trachoma 
control in 2006, are now awaiting WHO 
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ONCHOCERCIASIS AND TRACHOMA Continued
1  Drug donations by pharmaceutical 
companies: the historic, generous and 
timeless donation by Merck & Co. of 
Mectizan® for onchocerciasis control 
activities, and Pfizer Inc.’s donation of 
azithromycin for trachoma control in a 
number of affected countries. 
2  The development of cost-effective, 
rapid assessment methodologies 
which facilitated the mapping of the 
disease, such as: REMO (Rapid 
Epidemiological Mapping of 
Onchocerciasis) and REA (Rapid 
Epidemiological Assessment) for 
onchocerciasis, or the simplified grading 
scheme for trachoma, which facilitated 
the identification of priority areas.
3  Development of country databases 
for planning, monitoring and evalu-
ation: extensive, user-friendly, interactive 
databases, with detailed information on 
all endemic communities, target 
populations, nearby schools and health 
facilities, roads, etc.
4  Regular maintenance and updating 
of these databases in each country 
by well-trained and capable local teams. 
5 Secure and predictable financing 
over many years ensuring that planned 
activities will indeed be implemented: 
27 years for former OCP; ongoing since 
1992 and 1995, respectively, for OEPA 
and APOC. 
6  The establishment of a solid public-
private partnership and the meeting 
once a year of all stakeholders 
to review past and future programme 
activities and more importantly, to 
agree on next year’s budget for the 
programme.
7  The existence in each endemic 
country of well-structured and truly 
functional national Onchocerciasis 
Task Forces (NOTF), in which all stake-
holders (programme managers, NGDOs, 
Ministry of Health officials, researchers) 
meet regularly to plan, implement, 
monitor, and evaluate together all 
ongoing control activities. 
8  The promotion, generous support and 
regular use of operational research 
on all core aspects of programme 
implementation and its ‘feedback’ into 
ongoing operations. 
 9   A flexible and adaptive approach 
to mass distribution: e.g. mass 
distribution of Mectizan® has 
evolved from mobile strategies (very 
expensive and hardly sustainable) 
to community-directed treatment with 
ivermectin (high community 
ownership, very cost effective, and 
more likely to be sustainable). 
10  Active involvement of target 
communities: the prime benefici-
aries of the programme, i.e. 
affected communities, are actively 
involved at all stages of programme 
implementation (planning, community 
mobilisation, motivation of distrib-
utors, implementation, supervision, 
monitoring – including self-monitoring 
and supervision). A sharp contrast 
to what still prevails in many health 
intervention programmes, where 
targeted populations have no other 
role to play except that of passive 
but grateful participants of well-
designed and scientifically sound 
programmes developed on their 
behalf and for their benefit.
Ten reasons for success
Date Key event
1950s and 1960s Establishment of National Trachoma Control Programmes, mainly in  •	
endemic Asian, Middle Eastern, and Western Pacific countries  
1987 Introduction of the simplified grading scheme for trachoma •	
1996 Introduction of the SAFE strategy •	
1997 Launch of GET 2020  •	
1998 First donation of azithromycin and establishment of the International  •	
Trachoma Initiative
1999 Launch of VISION 2020 •	
Table 2. A chronological outline of the development of trachoma control programmes 
since the mid-twentieth century
The rapid progress and success achieved so far by onchocerciasis and trachoma control programmes 
is due to a combination of many contributing factors. These include:certification for the elimination of 
blinding trachoma as a public 
health problem throughout the 
country. Other countries still (The 
Gambia, Ghana, Mauritania, and 
Viet Nam) are also well on track to 
completing their trachoma control 
campaigns by 2010. 
Future prospects 
There is little doubt that, because 
of ongoing activities and the 
remarkable achievements to 
date, onchocerciasis and blinding 
trachoma may become the 
first major causes of needless 
blindness to achieve VISION 2020 
objectives within the year 
2020 endpoint. 
APOC’s operations are now 
scheduled to end by 2015. 
Current thinking and consensus is 
that, by then, the primary 
objective of the Programme, i.e. 
to establish sustainable national 
onchocerciasis control activities 
in all endemic countries, may not 
be achieved everywhere. This is 
mainly because programme 
implementation has been signifi-
cantly slowed down in war-torn 
countries, for obvious reasons, 
and in Central Africa where 
co-endemicity with Loa Loa and 
the risk of severe Central Nervous 
System complications has 
required extreme care and close 
medical supervision in the distri-
bution of Mectizan®.  
It is therefore imperative to ensure that all 
residual activities, including post-treatment 
surveillance, will have the financial and other 
logistic support needed for their completion 
or, failing that, for their integration into viable 
national health care systems.
Regarding trachoma control, the coming 
years should see a further expansion of the 
SAFE strategy and an increasing number of 
endemic countries with fully developed 
national plans.  Hopefully, both developments 
will be matched with a similar increase in 
financial resources available at country level.
Conclusion
Despite being two very different diseases, 
onchocerciasis and trachoma have a lot in 
common. Both are diseases of 
poverty, often affecting not just 
the poorest among the poor, but 
also the most difficult to reach in 
communities often described as 
“at the end of the road.” The 
challenges that they pose for their 
control are also quite similar, in 
that successful control of both 
diseases requires far more than 
an effective strategy or a freely 
available drug. Just as essential is 
highly coordinated work between 
all players involved, from donors 
and researchers, to people 
working in the field, not forgetting 
affected communities themselves.
Trachoma control presents us 
with an additional (and major) 
operational challenge, in that the 
success of the SAFE strategy 
requires a close and essential 
collaboration with non-medical 
experts for the implementation of 
its ‘F’ and ‘E’ components. Failing 
to fully implement all of its four 
components will mean running 
the risk of reducing the SAFE 
strategy into a purely medical 
effort that, most agree, is not 
likely to achieve optimal success 
– if at all – in our fight against 
blinding trachoma.
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Past experience has consistently shown 
that medical personnel tend to implement 
only the S (Surgery) and A (Antibiotic) 
components of the SAFE strategy.  
Reasons for this include:
The ‘S’ and ‘A’ components are the ones  •	
that health workers are most comfortable 
with or have skills for. 
The Ministry of Health rarely has the  •	
skills, expertise, and resources needed 
for the effective implementation of the 
‘F’ and ‘E’ components.
The ‘F’ and ‘E’ components require input  •	
from, and a close working relationship 
with, experts in the fields of education, 
community development, water, 
sanitation, and hygiene.
To this date, in many endemic countries,  •	
trachoma and public health experts have 
shown limited willingness for, and 
experience with, such a close and syner-
gistic collaboration with non-medical 
experts.
While there is no doubt that the ‘S’ and ‘A’ 
components remain important and urgent, 
the natural history of trachoma, in those 
parts of the world where it was once 
endemic, is also there to remind us that 
the disappearance of the disease had little 
to do with effective medical intervention 
(nonexistent at the time), but everything to 
do with improved socioeconomic living 
conditions, better sanitation, easy access 
to water, etc. 
Seen in that light, trachoma control 
presents to medical professionals a far 
greater challenge than any other cause of 
avoidable blindness. The imperative to 
make it succeed leaves us with no other 
option but to move out of our comfort zone 
and to proactively seek and reach out to 
other players, whose contribution to our 
global success may turn out at the end to 
be the ‘essential one’.
A humbling challenge indeed for 
some, but also a unique opportunity to 
develop tomorrow’s leaders, many of 
whom will be operating more and more 
(and not less) in resource-constrained 
environments, involved in more and 
more complex interventions such as, 
the Millennium Development Goals or 
the co-implementation of Neglected 
Tropical Diseases.
A challenge for the future: moving out of our comfort zone
The SAFE strategy, introduced in 1996, was one of 
the events that put the fight against trachoma back 
on the map
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